In September 2011, Photocure entered into a strategic collaboration with Ipsen, a global specialty-driven biopharmaceutical company focused on four franchises, including uro-oncology. Photocure has a strategic partnership with Ipsen for the commercialization of Hexvix in Europe, excluding the Nordic region.
Ipsen has a well established and growing uro-oncology franchise and will commercialize Hexvix through its dedicated urology specialists. Ipsen has its headquarter in Paris, France, and commercial presence in 49 countries.
Ipsen web page
In 2Q 2015: Photocure entered into an exclusive distribution agreement with Juno Pharmaceuticals, for the registration and commercialization of Hexvix in Australia and New Zealand. Juno Pharmaceuticals, a privately held global health care company, was founded in 2012 by a group of experienced international pharmaceutical executives and is a fast growing global specialty pharmaceutical company. With a primary focus on the hospital market channel, and a growing franchise in the urology segment, Juno has initiated the registration and precommercialization activities for Hexvix in the territory.
Juno web page
BioSyent Pharma Inc
In 3Q 2015: Photocure entered into an exclusive distribution agreement with BioSyent Pharma Inc. for the commercialization of Cysview in Canada. BioSyent is listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them. BioSyent will commercialize Cysview in Canada with their strong market position within urology and experienced team.
BioSyent web page